Making headway in dermatomyositis and so proud to see @IazsminBV in the @NEJM
242 refractory DM patients randomized to brepocitinib, a tyk2-jak1 inhibitor vs pbo and baseline meds. Brepo 30 mg with ⬆️total improvement, skin score, ⬇️GC, phys function ⬆️ cw pbo but ⬆️infections
Two years of a JAKi in GCA 📊
Dr. Dua and Dr. Boone share their thoughts on the latest data from a Phase 3 trial with a JAKi in GCA, including key long-term efficacy and safety outcomes. Sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/Wuu7xe5Xbl
REOVAS in print —>important study for INDUCTION in EGPA @TerrierBen
Rtx 1gx2 vs conventional tx (gc for ffs 0, cyc IV for ffs>0)
❌ RTX in non-severe dzs. ❌superior to cyc for severe dzs BUT patients did well (⬇️bvas and gc) ✅ no dif based on anca, new/relapsing status‼️
Register for the next ACR Convergence Replay recorded webinar—Controversies in the Treatment of ANCA-Associated Vasculitis—April 15, 7:00-8:15 PM ET. Live speaker Q&A post-session where you can ask questions & get further insights!
A study by Laura C. Arneson, MD (@LauraArneson4), and Brian D. Jaros, MD (@Dr_Brian_MD), examined various factors contributing to physician burnout, highlighting the link between EMR message volume and burnout. Read more:
https://t.co/7jELboztM1
Congratulations to our very own Brian Jaros, MD (@Dr_Brian_MD), recipient of @ACRheum’s 2024 Distinguished Fellow Award, presented during #ACR24 in Washington, DC. Congratulations, Dr. Jaros!
https://t.co/LYe20Lbtnn
Honored to have been named an ACR distinguished fellow amongst this group of amazing individuals!
Shoutout to my mentors, especially @anisha_dua who have guided my rheum journey and thank you to @ACRheum#ACR24
Congrats to all this year’s awardees!
Rct of > 200 patients with knee OA treated with usual care plus mtx vs pbo. Mtx titrated to 25mg weekly and showed improvement in pain score c/w PBO at 6 months w/o significant AEs! @Tuhina_Neogi@AM_Malf —will this change OA management?
Quick plug for a new rheumatology conference!
Great city at a great time of the year. I'll be there moderating and giving a few talks myself
Come join and say hello!
https://t.co/Spw2CFJYqH
✅ Very happy to share with you the link to our latest @Nature Review #Rheumatology on relapsing #polychondritis ⬇️ With @MertzP et Coll., we dig deep into the main differential diagnoses, including #VEXAS 👍 Read only at the following LINK:https://t.co/XIoTiD9sZe
@AKronbichler@RichardPAConway@RheumNow Agee-Eular-rtx OR cyc in severe disease. Also discussed combo rtx/cyc as potential option in the talk. For non severe disease cyc is associated with long term complications and “may be considered in non-organ threatening disease when alternatives rtx, Mtx, mmf cannot be used”
This #CME podcast led by @LCalabreseDO & @anisha_dua features a discussion on the use of immunosuppressants and corticosteroids for the induction and maintenance of EGPA remission >> https://t.co/xvyNCjrmXI
🔔Mentor member meeting with @EMEUNET are a fantastic way to meet rheumatologist from around the world, and learn from both experts & peers
🔔 Join us online on 20th & 22nd Nov for the #ACR23 edition
🔔Email: [email protected] with your name, country, preferred date